BioWorld Asia

March 10, 2010

Cellzome Lands Big GSK Deal: €475M for Inflammatory Diseases

LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International) BioWorld International Correspondent Read More

Genmab Shares Dive Sharply on Zalutumumab Phase III Miss

Ark Withdraws EU Application After EMEA Orders New Trial

NiCox, Bausch & Lomb Ink $179.5M Deal in Glaucoma

SpePharm Gets Product Rights, Sales Team from TopoTarget

New Ion Channel Possible Target for Atrial Fibrillation

ExonHit Emerges a Winner in Allergan, BMS Pain Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...